All In Biotech

Free tool

FAERS Monitor: Zeposia

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209899 or its brand name (Zeposia, Ozanimod Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

8,477

Serious

2,297

27% of reports

Hospitalization

631

Death reported

91

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue789
  • multiple sclerosis relapse595
  • drug ineffective553
  • headache526
  • product dose omission issue381
  • dizziness356
  • nausea288
  • diarrhoea267
  • colitis ulcerative263
  • pain259
  • back pain218
  • fall197
  • adverse event193
  • multiple sclerosis181
  • dyspnoea160

Reports by year received

View as table
YearReports
2020243
20211,903
20221,705
20231,533
20241,481
2025995
2026617

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,682 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
multiple sclerosis relapseSignal59521.720.111,676
colitis ulcerativeSignal26314.713.03,326
multiple sclerosisSignal1819.48.21,352
adverse eventSignal1935.24.5653
product dose omission issueSignal3813.22.9588
fatigueSignal7892.52.4746
back painSignal2182.32.0166
headacheSignal5262.11.9304
dizziness3561.81.6122
fall1971.51.329
pain2591.00.90
drug ineffective5531.01.01
diarrhoea2671.00.90
nausea2880.90.83
dyspnoea1600.70.621

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.